JP2018527570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018527570A5 JP2018527570A5 JP2018511233A JP2018511233A JP2018527570A5 JP 2018527570 A5 JP2018527570 A5 JP 2018527570A5 JP 2018511233 A JP2018511233 A JP 2018511233A JP 2018511233 A JP2018511233 A JP 2018511233A JP 2018527570 A5 JP2018527570 A5 JP 2018527570A5
- Authority
- JP
- Japan
- Prior art keywords
- peripheral blood
- cells
- positive
- combination
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021173852A JP7206352B2 (ja) | 2015-09-02 | 2021-10-25 | 併用療法のための患者の選択 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562213288P | 2015-09-02 | 2015-09-02 | |
| US62/213,288 | 2015-09-02 | ||
| US201562219612P | 2015-09-16 | 2015-09-16 | |
| US62/219,612 | 2015-09-16 | ||
| PCT/US2016/050274 WO2017041043A1 (en) | 2015-09-02 | 2016-09-02 | Selection of patients for combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173852A Division JP7206352B2 (ja) | 2015-09-02 | 2021-10-25 | 併用療法のための患者の選択 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018527570A JP2018527570A (ja) | 2018-09-20 |
| JP2018527570A5 true JP2018527570A5 (OSRAM) | 2019-12-12 |
Family
ID=58188549
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511233A Withdrawn JP2018527570A (ja) | 2015-09-02 | 2016-09-02 | 併用療法のための患者の選択 |
| JP2021173852A Active JP7206352B2 (ja) | 2015-09-02 | 2021-10-25 | 併用療法のための患者の選択 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173852A Active JP7206352B2 (ja) | 2015-09-02 | 2021-10-25 | 併用療法のための患者の選択 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11397184B2 (OSRAM) |
| EP (1) | EP3345002A4 (OSRAM) |
| JP (2) | JP2018527570A (OSRAM) |
| KR (2) | KR102631377B1 (OSRAM) |
| CN (2) | CN108139403B (OSRAM) |
| AU (2) | AU2016318136B2 (OSRAM) |
| BR (1) | BR112018003238A2 (OSRAM) |
| CA (1) | CA2994731C (OSRAM) |
| HK (1) | HK1258128A1 (OSRAM) |
| IL (1) | IL257355B (OSRAM) |
| MX (1) | MX2018002640A (OSRAM) |
| RU (1) | RU2018111407A (OSRAM) |
| WO (1) | WO2017041043A1 (OSRAM) |
| ZA (1) | ZA201800931B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018508593A (ja) * | 2015-03-20 | 2018-03-29 | シンダックス ファーマシューティカルズ，インコーポレイティド | がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ |
| RU2018130831A (ru) | 2016-01-28 | 2020-03-02 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Применение ингибиторов деацетилаз гистонов для улучшения иммунотерапии |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| JP7373991B2 (ja) | 2016-07-15 | 2023-11-06 | ビラクタ セラピューティクス，インク． | 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤 |
| EP3624848A1 (en) | 2017-05-19 | 2020-03-25 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| AU2019266231B2 (en) * | 2018-05-07 | 2025-08-21 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
| CN109251891B (zh) * | 2018-09-21 | 2021-10-22 | 苏州大学附属第一医院 | 一种cd40联合pd-l1及细胞因子扩增pbmc的方法 |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| ITUD20080058A1 (it) * | 2008-03-18 | 2009-09-19 | Thankstem S R L | Kit per la raccolta di sangue, preferibilmente periferico, per la produzione di cellule staminali |
| GB201015765D0 (en) * | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| EP3682896A1 (en) * | 2011-04-28 | 2020-07-22 | University of Southern California | Human myeloid derived suppressor cell cancer markers |
| UA124240U (uk) | 2011-09-02 | 2018-03-26 | Общєство С Огранічєной Отвєтствєностью "Новамєдіка" | Спосіб вибору пацієнта для подальшої терапії er-позитивного раку молочної залози |
| EP2872125A4 (en) * | 2012-07-10 | 2016-02-24 | Dana Farber Cancer Inst Inc | ANTIPROLIFERATIVE COMPOUNDS AND USES THEREOF |
| WO2014085461A1 (en) | 2012-11-29 | 2014-06-05 | The Penn State Research Foundation | Photodynamic dhsip anticancer therapeutic and immunomodulator |
| CN114099686B (zh) * | 2014-07-15 | 2024-04-16 | 约翰·霍普金斯大学 | 源自骨髓的抑制细胞的抑制和免疫检查点阻断 |
| JP2018508593A (ja) * | 2015-03-20 | 2018-03-29 | シンダックス ファーマシューティカルズ，インコーポレイティド | がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ |
-
2016
- 2016-09-02 WO PCT/US2016/050274 patent/WO2017041043A1/en not_active Ceased
- 2016-09-02 JP JP2018511233A patent/JP2018527570A/ja not_active Withdrawn
- 2016-09-02 US US15/756,898 patent/US11397184B2/en active Active
- 2016-09-02 RU RU2018111407A patent/RU2018111407A/ru unknown
- 2016-09-02 BR BR112018003238-7A patent/BR112018003238A2/en not_active Application Discontinuation
- 2016-09-02 KR KR1020187007043A patent/KR102631377B1/ko active Active
- 2016-09-02 KR KR1020247003086A patent/KR20240017973A/ko not_active Ceased
- 2016-09-02 CN CN201680050875.XA patent/CN108139403B/zh active Active
- 2016-09-02 MX MX2018002640A patent/MX2018002640A/es unknown
- 2016-09-02 HK HK19100418.3A patent/HK1258128A1/zh unknown
- 2016-09-02 CA CA2994731A patent/CA2994731C/en active Active
- 2016-09-02 CN CN202310449867.4A patent/CN116893262A/zh active Pending
- 2016-09-02 EP EP16843146.8A patent/EP3345002A4/en active Pending
- 2016-09-02 AU AU2016318136A patent/AU2016318136B2/en active Active
-
2018
- 2018-02-05 IL IL257355A patent/IL257355B/en unknown
- 2018-02-12 ZA ZA2018/00931A patent/ZA201800931B/en unknown
-
2021
- 2021-10-25 JP JP2021173852A patent/JP7206352B2/ja active Active
-
2022
- 2022-03-29 US US17/707,081 patent/US20230061048A1/en not_active Abandoned
- 2022-10-05 AU AU2022246409A patent/AU2022246409A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhu et al. | Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma | |
| Simonaggio et al. | Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab | |
| Cho et al. | Radiation-related lymphopenia as a new prognostic factor in limited-stage small cell lung cancer | |
| Mankor et al. | Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials | |
| Chihara et al. | Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL) | |
| RU2018111407A (ru) | Отбор пациентов для комбинированной терапии | |
| Chen et al. | Short leukocyte telomere length predicts poor prognosis and indicates altered immune functions in colorectal cancer patients | |
| Markovic et al. | Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma | |
| JP2013539857A5 (OSRAM) | ||
| Hu et al. | Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure | |
| Massa et al. | Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC | |
| Kataoka et al. | Carcinoembryonic antigen as a predictive biomarker of response to nivolumab in non–small cell lung cancer | |
| Li et al. | The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer/T‐cell lymphoma, nasal type | |
| Bhatt et al. | Central nervous system complications and outcomes after allogeneic hematopoietic stem cell transplantation | |
| Kobayashi et al. | Advanced human T‐cell leukemia virus type 1 carriers and early‐stage indolent adult T‐cell leukemia‐lymphoma are indistinguishable based on CADM 1 positivity in flow cytometry | |
| Hutterer et al. | Preoperative leucocytosis, thrombocytosis and anemia as potential prognostic factors in non-metastatic renal cell carcinoma | |
| Flörcken et al. | Myeloid-derived suppressor cells in human peripheral blood: optimized quantification in healthy donors and patients with metastatic renal cell carcinoma | |
| Barua et al. | Predictors of progression-free survival and overall survival in metastatic non-clear cell renal cell carcinoma: a single-center experience | |
| Li et al. | Prognostic significance of BCL-2 and BCL-6 expression in MYC-positive DLBCL | |
| Huffman et al. | Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders | |
| Miyashiro et al. | Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort | |
| Xie et al. | Clinical analysis and prognostic significance of lymphoma-associated hemophagocytosis in peripheral T cell lymphoma | |
| Yumioka et al. | Response to platinum-based chemotherapy rechallenge for patients with pembrolizumab-refractory urothelial carcinoma | |
| Pellegrino et al. | Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient | |
| Kwon et al. | Clinical features and treatment of collecting duct carcinoma of the kidney from the korean cancer study group genitourinary and gynecology cancer committee |